125 related articles for article (PubMed ID: 15864278)
1. Molecular genetics of multiple endocrine neoplasia types 1 and 2.
Marx SJ
Nat Rev Cancer; 2005 May; 5(5):367-75. PubMed ID: 15864278
[TBL] [Abstract][Full Text] [Related]
2. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
Eng C; Clayton D; Schuffenecker I; Lenoir G; Cote G; Gagel RF; van Amstel HK; Lips CJ; Nishisho I; Takai SI; Marsh DJ; Robinson BG; Frank-Raue K; Raue F; Xue F; Noll WW; Romei C; Pacini F; Fink M; Niederle B; Zedenius J; Nordenskjöld M; Komminoth P; Hendy GN; Mulligan LM
JAMA; 1996 Nov; 276(19):1575-9. PubMed ID: 8918855
[TBL] [Abstract][Full Text] [Related]
3. MEN 2B CASES WITH ATYPICAL PRESENTATION, UNUSUAL CLINICAL COURSE AND A LITERATURE REVIEW.
Keskin Ç; Canpolat AG; Canlar Ş; Bahçecioğlu Mutlu AB; Erdoğan MF
Acta Endocrinol (Buchar); 2023; 19(2):260-266. PubMed ID: 37908885
[TBL] [Abstract][Full Text] [Related]
4. LncRNA MALAT1 signaling pathway and clinical applications in overcome on cancers metastasis.
Mazarei M; Shahabi Rabori V; Ghasemi N; Salehi M; Rayatpisheh N; Jahangiri N; Saberiyan M
Clin Exp Med; 2023 Dec; 23(8):4457-4472. PubMed ID: 37695391
[TBL] [Abstract][Full Text] [Related]
5. Impact of Vitamin D Deficiency on Tumor Aggressiveness in Neuroendocrine Neoplasms.
Albertelli M; Petolicchio C; Brasili S; Pogna A; Boschetti M; Luciano G; Campana D; Gay S; Veresani A; Ferone D; Vera L
Nutrients; 2023 Aug; 15(17):. PubMed ID: 37686803
[No Abstract] [Full Text] [Related]
6. Persistent hyperparathyroidism secondary to ectopic parathyroid adenoma in lung: Case report.
Valizadeh M; Ebadinejad A; Amouzegar A; Zakeri A
Front Endocrinol (Lausanne); 2022; 13():988035. PubMed ID: 36583007
[TBL] [Abstract][Full Text] [Related]
7. Novel germline variants of CDKN1B and CDKN2C identified during screening for familial primary hyperparathyroidism.
Mazarico-Altisent I; Capel I; Baena N; Bella-Cueto MR; Barcons S; Guirao X; Albert L; Cano A; Pareja R; Caixàs A; Rigla M
J Endocrinol Invest; 2023 Apr; 46(4):829-840. PubMed ID: 36334246
[TBL] [Abstract][Full Text] [Related]
8. Loss of MEN1 leads to renal fibrosis and decreases HGF-Adamts5 pathway activity via an epigenetic mechanism.
Jin B; Zhu J; Zhou Y; Liang L; Yang Y; Xu L; Zhang T; Li P; Pan T; Guo B; Chen T; Li H
Clin Transl Med; 2022 Aug; 12(8):e982. PubMed ID: 35968938
[TBL] [Abstract][Full Text] [Related]
9. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F; Neha K; Chauhan G
Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Tumors: a Relevant Clinical Update.
Rizen EN; Phan AT
Curr Oncol Rep; 2022 Jun; 24(6):703-714. PubMed ID: 35254612
[TBL] [Abstract][Full Text] [Related]
11. RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation.
Yue CH; Oner M; Chiu CY; Chen MC; Teng CL; Wang HY; Hsieh JT; Lai CH; Lin H
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34207842
[TBL] [Abstract][Full Text] [Related]
12. Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.
Fancelli S; Caliman E; Mazzoni F; Brugia M; Castiglione F; Voltolini L; Pillozzi S; Antonuzzo L
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806299
[TBL] [Abstract][Full Text] [Related]
13. Familial Hyperparathyroidism.
Blau JE; Simonds WF
Front Endocrinol (Lausanne); 2021; 12():623667. PubMed ID: 33716975
[TBL] [Abstract][Full Text] [Related]
14. Integrated multi-omics profiling of nonfunctioning pituitary adenomas.
Wei Z; Zhou C; Li M; Huang R; Deng H; Shen S; Wang R
Pituitary; 2021 Jun; 24(3):312-325. PubMed ID: 33205234
[TBL] [Abstract][Full Text] [Related]
15. Fine-Tuning of GLI Activity through Arginine Methylation: Its Mechanisms and Function.
Abe Y; Tanaka N
Cells; 2020 Aug; 9(9):. PubMed ID: 32859041
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Molecular Genetics of Primary Hyperparathyroidism.
Simonds WF
Horm Metab Res; 2020 Aug; 52(8):578-587. PubMed ID: 32227318
[TBL] [Abstract][Full Text] [Related]
17. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Tirrò E; Martorana F; Romano C; Vitale SR; Motta G; Di Gregorio S; Massimino M; Pennisi MS; Stella S; Puma A; Gianì F; Russo M; Manzella L; Vigneri P
Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31540307
[TBL] [Abstract][Full Text] [Related]
18. Targeting RET-rearranged non-small-cell lung cancer: future prospects.
Bronte G; Ulivi P; Verlicchi A; Cravero P; Delmonte A; Crinò L
Lung Cancer (Auckl); 2019; 10():27-36. PubMed ID: 30962732
[TBL] [Abstract][Full Text] [Related]
19. Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives.
Khatami F; Tavangar SM
Biomark Insights; 2018; 13():1177271918785129. PubMed ID: 30013307
[TBL] [Abstract][Full Text] [Related]
20. Genomic Alterations in Sporadic Pituitary Tumors.
Bi WL; Larsen AG; Dunn IF
Curr Neurol Neurosci Rep; 2018 Feb; 18(1):4. PubMed ID: 29396598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
